Compare Huntington Bancshares Incorporated (HBAN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Johnson & Johnson — how do they compare? Huntington Bancshares Incorporated trades at $18.12 (market cap $36.62B), while Johnson & Johnson trades at $249.22 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 16.4× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.43%). Which is the better fit depends on your goals.
| HBAN | JNJ | |
|---|---|---|
Market Cap | $36.62B | $598.96B |
Sector | Financials | Health |
52-Week High | $19.27 | $267.24 |
52-Week Low | $15.02 | $164.36 |
Dividend Yield | 3.43% | 2.15% |
Volume | — | 6,156,228 |
Enterprise Value | — | $631.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.07, down 0.99% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, with revenue growth to $8.13 billion in 2025. Recent news highlights expansion in Texas and a strong fintech partnership award.
HBAN presents a mixed outlook; analyst consensus is a Buy with a $20.25 price target, implying upside, but risks include integration challenges from acquisitions and competitive pressures in regional banking. Earnings growth and margin stability are key catalysts, though debt levels have risen steadily.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
